{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-073324","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.656622+00:00","generated_at":"2026-06-04T10:19:27.238068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Disc Medicine reports FY2023 net loss $76.4M, cash $360.4M; AURORA topline data expected March/April 2024","bullets":["Cash and cash equivalents $360.4M at Dec 31, 2023, providing runway well into 2026.","Net loss of $76.4M for FY2023 vs $46.8M in 2022, driven by higher R&D costs ($69.3M vs $33.4M).","Topline results from AURORA phase 2 study of bitopertin in EPP expected March/April 2024.","Updated phase 1b/2 data for DISC-0974 in anemia of myelofibrosis expected 1H 2024.","Appointed Jean Franchi as CFO, Pamela Stephenson as CCO, promoted Jonathan Yu to COO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-073324","json":"https://secwatch.observer/filing/0001193125-24-073324.json","markdown":"https://secwatch.observer/filing/0001193125-24-073324.md","text":"https://secwatch.observer/filing/0001193125-24-073324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/0001193125-24-073324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/d795577d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:19:27.238068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa7dafe418b495a905e5024fb1a4d6432dc6cb10","claim":"Disc Medicine, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income Net loss was $76.4 million.","evidence_excerpt":"Disc Medicine, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312524073324/0001193125-24-073324-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $76.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}